Breaking News

AstraZeneca Unit Acquires AlphaCore Pharma

April 3, 2013

Adds early-stage cardiovascular drug

AstraZeneca’s MedImmune unit has acquired AlphaCore Pharma, a privately held U.S. biotechnology company developing a new type of cholesterol medicine. Financial details were not disclosed.
 
AlphaCore’s lead drug candidate ACP-501, a genetically engineered liver-derived enzyme called LCAT, completed Phase I trials last year. ACP-501 is being developed to help manage cholesterol to reduce the risk of heart attacks and strokes. It could also play a role in a rare, hereditary disorder called familial LCAT deficiency in which the LCAT enzyme is absent.
 
"As the science in this area continues to evolve, we are committed to exploring unique pathways that could lead to new combination or standalone therapies for patients living with chronic and acute cardiovascular diseases," said MedImmune head Bahija Jallal.

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.